Progress in Prevention

Access to Innovative Medicine

A Preventive Cardiovascular Nurses Association Position Statement to Reduce the Barriers

Cindy Lamendola, MSN, ANP, RN, FAHA, FPCNA; Mary Ann Champagne, MSN, CNS, RN, FAHA, FPCNA; Jane Nelson Worel, MS, ANP, RN, FAHA, FPCNA; Lola A. Coke, PhD, ACNS-BC, CVRN-BC, FAHA, FPCNA, FAAN

For decades, cardiovascular disease (CVD) has been the number one cause of death in the United States. The American Heart Association’s most recent 2017 statistics lists CVD as the underlying cause of nearly 801,000 deaths in the United States, about 1 of every 3 deaths. In addition to this staggering mortality data, morbidity is also taking a huge toll. About 92.1 million American adults are living with some form of CVD or the after-effects of stroke. Direct and indirect costs of CVD and stroke are estimated to total more than $316 billion, which includes both health expenditures and lost productivity.¹

The mission of the Preventive Cardiovascular Nurses Association (PCNA) is to promote all nurses as leaders in CVD prevention and management across the lifespan. In conjunction with this mission, one of PCNA’s primary organizational goals is to support and advocate for the utilization and dissemination of research and evidence-based practice guidelines in CVD risk reduction and disease management. Members of the PCNA, who are employed in diverse healthcare settings including hospitals and outpatient clinics, care for a wide variety of patients with CVDs. These patients often have cardiovascular risk factors, such as hypertension and dyslipidemia, including familial hypercholesterolemia and/or diabetes. They have experienced myocardial infarctions, undergone heart surgery or stent placement, or have diagnoses such as heart failure or atrial fibrillation, including those on chronic oral anticoagulant therapies. Our members have a significant impact on patient outcomes because they promote and deliver evidenced based cardiovascular care.

Americans’ ratings of the honesty and ethical standards of 22 occupations find nurses at the top of the list. For the 16th consecutive year in a recently published Gallop poll, nurses were the most trusted profession in the country.² In addition, nurses are uniquely positioned to make a difference in the lives of patients as advocates for healthcare policy that impacts access to healthcare and innovative medicines.

Barriers to Accessing Innovative Medications

As new treatments for CVD and stroke are found to be scientifically valid and improve outcomes and are incorporated in evidence based guidelines, it is imperative these innovative therapies are available to all eligible patients who agree to these treatments.³,⁴

Unfortunately, the costs of these innovative therapies are a key barrier to accessibility. Gaining access to these treatments is challenging and time consuming for both the provider and patient. Healthcare insurers require prior authorization for specialty treatments. This has become more common as a measure to control

Cindy Lamendola, MSN, ANP, RN, FAHA, FPCNA
Nurse Practitioner and Clinical Research Coordinator Stanford Medicine, Division of Cardiovascular Medicine, Palo Alto, California.

Mary Ann Champagne, MSN, CNS, RN, FAHA, FPCNA
Clinical Nurse Specialist, Preventive Cardiology, Division of Cardiovascular Medicine Stanford Medical Center, Palo Alto, California.

Jane Nelson Worel, MS, ANP, RN, FAHA, FPCNA
Director of Education, Preventive Cardiovascular Nurses Association, Madison, Wisconsin.

Lola A. Coke, PhD, ACNS-BC, CVRN-BC, FAHA, FPCNA, FAAN
Associate Professor, Adult Health and Gerontological Nursing, Rush University College of Nursing, Chicago, Illinois.

Correspondence
Lola A. Coke, Adult Health and Gerontological Nursing, Rush University College of Nursing, 600 S. Paulina, Suite 1080, Chicago, IL 60612 (Lola_Coke@rush.edu).

DOI: 10.1097/JCN.0000000000000492
costs and promote utilization of specialty treatments according to evidence-based guidelines. Prior authorization can negatively affect care by delaying the initiation and continuation of medication, thus impacting patient satisfaction and clinical outcomes. This process places excessive burden on providers and their practice staff, disrupts workflow, and diverts valuable resources away from direct patient care. Delay or denial of proper treatment to decrease risk of progression of disease may result in an increase in morbidity, resulting in hospitalizations and causing additional healthcare costs. As an example, high-risk CVD patients unable to reach low-density lipoprotein lowering goals and not able to access innovative therapies are at increased risk for a first time or reoccurrence of a cardiovascular or stroke event. Affordable and timely access to these therapies is essential for all patients.

**Nursing Role**

Along with current knowledge of the criteria in determining appropriate patient selection, a critical concept is that of patient-centered care. Patient-centered care is defined as an approach to “providing care that is respectful of and responsive to individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions.”

The basic tenet is that patient-centered care requires shared and informed decision making. Providers need to incorporate a decision-making process, stressing the importance of collaboration and effective communication between themselves and the patient. Shared decision making is the process by which a healthcare provider communicates personalized information to the patient about the following:

- Options
- Outcomes
- Probabilities
- Scientific uncertainties of available treatment options

The patient communicates his or her values and the relative importance that he or she places on benefits and harms.

Initially, healthcare providers can minimize the need for specialty medications by treating patients with current guideline therapies to the maximally tolerated level (using generics when possible). In addition, the provider needs to address lifestyle management and medication adherence. This typically allows most patients to achieve goals and limit the need for specialty medications thereby reducing cost to the patient and society.

When an eligible patient receives innovative medicine, providers need to continue to manage risk reduction through these additional therapies as well as continued lifestyle changes and medication adherence.

Nurses are instrumental in the prior authorization process. They develop systems within the work place to track and streamline the process. Along with the healthcare team, they develop and define roles and provide training. This effort needs to be continually managed, and resources updated, to achieve success in this process.

**Position**

On the national landscape, PCNA is in alignment with the priorities and initiatives expressed by many of our collaborating organizations that have published position statements on patient access to healthcare and innovative medications. These organizations include, but are not limited to, the following: American Association of Heart Failure Nurses, American College of Cardiology, American Heart Association, American Diabetes Association, The Familial Hypercholesterolemia Foundation, and the American Medical Association.

All patients should have access to guideline directed innovative medical therapies to optimize CVD risk reduction and disease management. Nurses, including advance practice providers, are on the frontlines for the delivery of patient-centered care. As an integral component of our mission, PCNA provides extensive and comprehensive education and clinical tools to inform and educate our members of relevant healthcare issues and continually updated guidelines. An essential role in implementing this education and using clinical tools is utilizing evidenced-based treatments that may include these innovative medications for appropriate patients. We posit the following:

1. **Our mission is to promote nurses as leaders in CVD prevention and management across the lifespan.**

2. **Collaboration with other professional organizations to advocate and promote healthcare policy for advancement of CVD risk reduction and access to healthcare for all individuals is key.**

3. **Nurses play a critical role in accessing innovative therapies that improve CVD and stroke outcomes.**

4. **Patient-centered care and shared decision making are essential components to implementing cardiovascular risk reduction strategies.**

The PCNA has engaged in a yearlong campaign to raise awareness about the challenges and barriers that cardiovascular nurses and healthcare providers face in helping patients access new, innovative cardiovascular medicines. This campaign has included a lecture series presented across the country to discuss barriers and strategies to obtain these innovative medicines. An important aim of this campaign has been to provide a forum for dialogue, support, problem solving, possible solutions, and best practice tips as advanced practice providers work to provide these innovative medicines to their patients. In addition, PCNA has developed a clinical tip sheet/tool on access to innovative medicines. This tool is available via http://pcna.net/access.
Conclusion

The PCNA will continue to raise awareness about, and advocate for, reducing the challenges and barriers that cardiovascular nurses and all healthcare providers face in assisting all patients access to innovative medicine for healthcare, CVD risk reduction treatment and management. The PCNA will play a strong role in advocating for access to innovative medicines to decrease CVD morbidity and mortality and developing the necessary resources that providers need to effectively obtain innovative medical therapies for cardiovascular patients.

REFERENCES


Social Support, Unstable Angina, and Stroke as Predictors of Depression in Patients With Coronary Heart Disease: Erratum

In the article that appeared on page 179 of the March/April 2018 issue, the affiliation of the first author (Su, S.-F.) should be “Department of Nursing, National Taichung University of Science and Technology, Taiwan (R.O.C.).”

In Table 3, the following values should be presented in bold face: .004b, .017a, .042a, .002b, .001c, and .026a.

REFERENCE


DOI: 10.1097/JCN.0000000000000492